The publishing team were exceptionally busy throughout ESMO, working around the clock to capture the meeting’s most impactful scientific insights. Across the week, they conducted an outstanding 154 interviews with leading KOLs – an effort that reflects the scale of innovation and expertise showcased at this year’s congress.
This year at ESMO, the VJOncology publishing team were joined by colleagues from our marketing and business teams, creating a strong on-site presence that extended well beyond the press area. With our booth buzzing throughout the meeting, we had the chance to engage in meaningful conversations with clinicians and industry experts from around the world.
The content from the congress is currently hosted on our dedicated ESMO page on VJOncology . If you are interested in supporting Independent Medical Education through our channels, please get in touch here .
Our Editors’ Top Picks from ESMO 2025
At every major congress, our editors handpick the abstracts they feel offer the most practice-changing insights or the most exciting developments.
Here are the picks from ESMO:
Phase Ia/b trial of IMA203, a PRAME-directed TCR therapy, in uveal melanoma
Sapna Patel, MD, Colorado Cancer Center, Aurora, CO, USA
PSMAddition: 177Lu-PSMA-617 plus ADT and ARPI in PSMA-positive mHSPC
Scott Tagawa, MD, MS, FACP, Weill Cornell Medical Center, New York, NY, USA
T-DXd vs T-DM1 in high-risk HER2+ breast cancer: DESTINY-Breast05 interim data
Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, USA
RC48-C016: disitamab vedotin & toripalimab vs chemotherapy in HER2+ la/mUC
Andrea Necchi, MD, IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy
OptiTROP-Lung04: sacituzumab tirumotecan in EGFR-mutated NSCLC
Antonio Passaro, MD, PhD, Istituto Europeo di Oncologia, Milan, Italy
‘Ask the Expert’ Feature at ESMO 2025
Our ‘Ask the Expert’ series was a new feature for ESMO 2025. It was introduced at the congress to gain practice-focused insights directly from leading clinicians across tumour types.
Highlights from the sessions:
Breast cancer with Stephanie Graff, MD (Brown University):
- Evolving roles of CDK4/6 inhibitors in HR+/HER2- breast cancer,
- Managing endocrine therapy-related toxicities
- Trial-access barriers for patients
Breast cancer with Kevin Kalinsky, MD, MS (Winship Cancer Institute, Emory University):
- Which patients with HR+/HER2- early-stage breast cancer benefit most from endocrine therapy
- When chemotherapy might be avoidable
- Treatment stratification
Bladder cancer with Petros Grivas, MD, PhD (University of Washington)
- Perioperative immunotherapy in muscle-invasive disease
- ADC sequencing
- Impact of molecular profiling in urothelial carcinoma
Each of these sessions underscores our commitment to capturing the real-time questions clinicians face and translating them into accessible, expert-led conversations.
Whether you were in Berlin or watching remotely, our goal is to give you the ‘in-room’ feeling – the diversity of thought, the momentum of progress, and to help you stay ahead of the curve.
About VJOncology
The Video Journal of Oncology (VJOncology) is a leader in oncology news and education, providing healthcare professionals from around the globe with easy access to the latest updates in solid tumor research and expert opinion. Our Editorial Board and Team work closely to capture the most important and relevant information from major congresses and meetings, presenting this in engaging and easily-digestible digital formats for community oncologists to explore.
The continued success of VJOncology is in no small part down to independent support from industry. If you’re interested in supporting one of our Disease Channels or one of our other medical education programs, please get in contact with us here .
Written by Henry Shippey, Partnerships Manager at Magdalen Medical Publishing
